Hyperion Therapeutics Inc., of Brisbane, Calif., and Clal Biotechnology Industries Ltd. (CBI), of Ramat Gan, Israel, said they entered an interim agreement in order to attempt to resolve the disputes between them and to allow CBI to evaluate whether there is any clinical efficacy to, and a potential regulatory path forward for, Diapep277 that a party other than Hyperion may wish to pursue.